Annual report pursuant to Section 13 and 15(d)

Note 12 - Notes Payable (Details Textual)

Note 12 - Notes Payable (Details Textual)							1 Months Ended						12 Months Ended
Note 12 - Notes Payable (Details Textual)	Apr. 09, 2018 USD ($)	Mar. 31, 2017 USD ($)	Mar. 03, 2017 USD ($)	Jul. 01, 2016	Jun. 22, 2016 USD ($)	Mar. 31, 2014	Nov. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	May 31, 2015 USD ($) $ / shares	Mar. 31, 2014	Jun. 30, 2013 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jun. 25, 2013 USD ($)	Jul. 31, 2012 USD ($)
Repayments of Notes Payable													$ 395,573	$ 59,753,740
Interest Expense, Debt, Total													161,000	159,000
Notes Payable, Current, Total								$ 2,353,639					316,074	2,353,639
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs													153,000	134,000
Disposal Group, Including Discontinued Operation, Interest Expense														1,706,491
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months													316,000
CRG [Member]
Draws on Letter of Credit	$ 7,100,000
Judicial Ruling [Member] \| CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount			$ 7,000,000					7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration								4,100,000					4,100,000
Maximum [Member] \| Judicial Ruling [Member] \| CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value			66,000,000					66,000,000
Platinum Loan Agreement [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability								0					0	0
Convertible Debt, Fair Value Disclosures								2,000,000					0	2,000,000
Platinum Loan Agreement [Member] \| PPCO [Member]
Line of Credit Facility, Maximum Borrowing Capacity																		$ 50,000,000
Line of Credit Facility, Current Borrowing Capacity																		35,000,000
Line of Credit Facility, Increase Additional Borrowings Terms Not Negotiated																		$ 15,000,000
Proceeds from Lines of Credit, Total																	$ 8,000,000
Repayments of Debt			7,700,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total													0	(153,000)
Platinum-Montaur Life Sciences LLC Litigation [Member]
Line of Credit Facility, Current Borrowing Capacity												$ 35,000,000
Debt Instrument, Interest Rate, Stated Percentage						10.00%				10.00%	10.00%	10.00%
InterestRateInAdditionToAmendedAgreement												0.125%
Repayments of Notes Payable												$ 4,800,000
Stock for Stock Conversion Number of Shares Converted \| shares												2,364.9
Number of Common Shares Underlying Series B Preferred Stock \| shares												7,733,223
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock \| shares												3,270
Debt Instrument, Convertible, Threshold Trading Days										10
Debt Instrument, Convertible, Stock Price Trigger \| $ / shares										$ 2.53
Line of Credit Facility, Decrease Forgiveness Interest Percentage				6.00%
Interest Expense, Debt, Excluding Amortization													153,000	265,000
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate										6.75%	6.75%	6.75%
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Oxford Financing Rate [Member]
Debt Instrument, Basis Spread on Variable Rate						0.125%
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Interest Rate Pursuant to CRG Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate										0.125%
Term Loan Agreement [Member] \| Judicial Ruling [Member] \| CRG Loan Agreement, Texas Case [Member]
Repayments of Debt	$ 7,100,000	$ 59,000,000
Term Loan Agreement [Member] \| CRG [Member]
Debt Instrument, Interest Rate, Stated Percentage										14.00%
Interest Expense, Debt, Excluding Amortization															$ 1,800,000	$ 1,800,000
Repayments of Debt			59,000,000
Debt Instrument, Face Amount										$ 50,000,000
Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions										$ 10,000,000
Percentage of Per Annum Interest Paying in Cash										10.00%
Percentage of Per Annum Interest as Compounded Interest										4.00%
Debt Instrument, Number of Quarterly Payments										8
Debt Instrument Payment Terms Payment Period										2 years
Debt Instrument, Covenant Compliance, Income (Loss) Earnings Before Interest, Taxes, Depreciation, and Amortization, Minimum										$ 5,000,000
Debt Instrument, Covenant Compliance Sales Revenue Minimum Next Twelve Months															$ 22,500,000
DebtInstrumentCovenantComplianceTargetRevenueMinimum										$ 45,000,000
Debt Instrument, Covenant Compliance Cure Right Ratio										2.5
Debt Instrument, Covenant Compliance Liquidity Minimum										$ 5,000,000
Debt Instrument, Interest Rate in the Event of Default										18.00%
Primary Bank Account Cash Taken Possession Of By Creditor					$ 4,100,000
Payments to Prepayment Premium and Backend Facility Fee on Claims of Default					3,900,000
Payments to Principal Balance of Debt on Claims of Default					$ 189,000
Term Loan Agreement [Member] \| CRG [Member] \| Judicial Ruling [Member] \| CRG Loan Agreement, Texas Case [Member]
Repayments of Debt		$ 59,000,000	59,000,000
Term Loan Agreement [Member] \| CRG [Member] \| Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount			$ 66,000,000					66,000,000						66,000,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Notes Payable, Current, Total								$ 318,000					316,000	318,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] \| IPFS [Member]
Debt Instrument, Interest Rate, Stated Percentage							5.10%		4.00%
Debt Instrument, Face Amount							$ 393,000		$ 396,000
Debt Instrument, Term							300 days		300 days
Debt Instrument, Periodic Payment, Total							$ 40,000		$ 40,000
Interest Expense, Debt, Total													$ 8,000	$ 12,000